PRF Technologies Ltd.

PRFX

IL0011651580

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 25/06/2026 +04			5-day change	1st Jan Change
1.410 ^USD	-2.76%		-23.78%	-56.06%

06-16	Top Premarket Decliners	MT
05-29	Top Premarket Gainers	MT

Top Premarket Decliners

Published on 06/16/2026 at 03:34 pm +04

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about PRF Technologies Ltd.

06-16	Top Premarket Decliners	MT
05-29	Top Premarket Gainers	MT
05-28	PRF Technologies Ltd. Advances DeepSolar Predict Toward Commercial Launch As AI Platform Targets Revenue Optimization Across Renewable Energy Markets	CI
05-26	PRF Technologies Reports Positive Preclinical Results for PRF-110 in Head-To-Head Study with ZYNRELEF	CI
04-28	PRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical Trial	CI
04-06	Top Premarket Gainers	MT
03-27	PRF Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	PRF Technologies Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-17	PRF Technologies Ltd. and Blade Ranger Ltd. Enter Commercial Collaboration Agreement	CI
03-17	Prf Technologies Ltd. announces commercial collaboration agreement with Blade Ranger to accelerate large-scale Deepsolar commercial engagements	RE
03-04	PRF Technologies Ltd appoints Efi Cohen-Arazi as interim CEO	RE
03-04	PRF Technologies Ltd. Announces CEO Changes, Effective February 25, 2026	CI
03-04	PRF Technologies Ltd. Appoints Eyal Broder as CFO, Effective February 25, 2026	CI
03-04	PRF Technologies Ltd. Announces Board and Committee Changes, Effective February 25, 2026	CI
02-18	DeepSolar Announces Its First Commercial Due Diligence Engagement with EDF Power Solutions Israel	CI

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustainedâ€‘release drugâ€‘delivery platforms that combine proven generic medicines with proprietary extendedâ€‘release systems to improve patient outcomes. One of the Company's products is PRFâ€‘110 - a ropivacaineâ€‘based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bioâ€‘erodible drugâ€‘release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AIâ€‘powered monitoring, forecasting, and optimisation tools for solar asset performance.

Employees

Sector

Pharmaceuticals

More about the company